Table 1 Outcome of recombinant hIFN-β... | American Society of Hematology

Table 1

Outcome of recombinant hIFN-β treatment of HL-60 leukemic mice

Treatment cohort	Proportion of animals with significant disease*	Peak plasma hIFN-β levels, IU/mL	Trough plasma hIFN-β levels, IU/mL
Controls	10/10	< 0.5	< 0.5
Subcutaneous hIFN-β	4/4	< 0.5	< 0.5
Intravenous hIFN-β	8/10†	400 ± 100	< 0.5

Treatment cohort	Proportion of animals with significant disease*	Peak plasma hIFN-β levels, IU/mL	Trough plasma hIFN-β levels, IU/mL
Controls	10/10	< 0.5	< 0.5
Subcutaneous hIFN-β	4/4	< 0.5	< 0.5
Intravenous hIFN-β	8/10†	400 ± 100	< 0.5

Peak levels were measured at 2 hours after injection; trough at 24 hours.

More than 30% infiltration.

Two early deaths from radiation toxicity.